<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002120</url>
  </required_header>
  <id_info>
    <org_study_id>224A</org_study_id>
    <secondary_id>TMTX A009</secondary_id>
    <nct_id>NCT00002120</nct_id>
  </id_info>
  <brief_title>Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia</brief_title>
  <official_title>Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jacobus Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety of the combination of trimetrexate glucuronate (TMTX) and dapsone with&#xD;
      leucovorin protection versus trimethoprim/sulfamethoxazole (TMP/SMX) in patients with AIDS&#xD;
      and moderately severe Pneumocystis carinii pneumonia (PCP). To determine the pharmacokinetic&#xD;
      parameters of TMTX, leucovorin, and dapsone and of TMP/SMX when given to patients with AIDS&#xD;
      and moderately severe PCP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetrexate glucuronate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Empiric therapy for other opportunistic pulmonary infection (TB or fungi) for the&#xD;
             first 72 hours of study enrollment ONLY, until presence of suspected pathogens can be&#xD;
             confidently excluded.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS.&#xD;
&#xD;
          -  Confirmed diagnosis of PCP.&#xD;
&#xD;
          -  Alveolar-arterial differences in dissolved oxygen &gt;= 35 mm Hg but &lt; 55 mm Hg on room&#xD;
             air.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Severe renal or hepatic dysfunction.&#xD;
&#xD;
          -  Serious or life-threatening intolerance to TMP/SMX, TMTX, or dapsone.&#xD;
&#xD;
          -  Concurrent pneumothorax.&#xD;
&#xD;
          -  Active pulmonary tuberculosis or other inadequately treated opportunistic pulmonary&#xD;
             infection (e.g., Cryptococcus neoforms, CMV). NOTE:&#xD;
&#xD;
          -  Identification of Mycobacterium avium or CMV in sputum or BAL fluid does not exclude,&#xD;
             since these organisms may be present without causing disease.&#xD;
&#xD;
          -  Pulmonary Kaposi's sarcoma.&#xD;
&#xD;
          -  Active opportunistic infections or malignancies requiring induction therapy with bone&#xD;
             marrow suppressive drugs (e.g., ganciclovir) or hepatotoxic drugs (e.g.,&#xD;
             chemotherapy).&#xD;
&#xD;
          -  Unable to have arterial blood gases on room air obtained at baseline.&#xD;
&#xD;
          -  Unwilling to undergo bronchoscopy, if sputum induction does not reveal Pneumocystis&#xD;
             carinii.&#xD;
&#xD;
          -  Suspected malabsorption (e.g., ileus or severe diarrhea with &gt; 6 stools/day).&#xD;
&#xD;
          -  Known absence of G6PD activity.&#xD;
&#xD;
          -  Large volume (1.0 to 1.5 liters) of intravenous fluid (5 percent in water) per 24&#xD;
             hours is medically inadvisable.&#xD;
&#xD;
          -  Unwilling to comply with study design.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Induction therapy with bone marrow suppressive drugs (e.g., ganciclovir) or&#xD;
             hepatotoxic drugs (e.g., chemotherapy).&#xD;
&#xD;
          -  AZT, ddI, ddC, d4T, or other antiretroviral therapy.&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
        Prior history of serious or life-threatening intolerance to TMP/SMX. (NOTE:&#xD;
&#xD;
          -  Patients with less severe reactions may be included at the discretion of the&#xD;
             investigator and primary care provider.)&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  More than 24 hours of systemic anti-PCP therapy within 2 weeks prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles County / Health Research Assoc / Drew Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <keyword>Trimetrexate</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Dapsone</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Dapsone</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimetrexate</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

